Janus Henderson Group PLC Acquires 1,978,839 Shares of Geron Corporation $GERN

Janus Henderson Group PLC increased its holdings in Geron Corporation (NASDAQ:GERN) by 826.7% during the first quarter, Holdings Channel.com reports. The firm owned 2,218,196 shares of the biopharmaceutical company’s stock after acquiring an additional 1,978,839 shares during the quarter. Janus Henderson Group PLC’s holdings in Geron were worth $3,304,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Principal Financial Group Inc. increased its stake in shares of Geron by 20.5% during the first quarter. Principal Financial Group Inc. now owns 39,519 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 6,713 shares during the period. Sei Investments Co. lifted its stake in Geron by 23.0% in the first quarter. Sei Investments Co. now owns 41,891 shares of the biopharmaceutical company’s stock worth $62,000 after acquiring an additional 7,840 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Geron by 2.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 392,534 shares of the biopharmaceutical company’s stock valued at $627,000 after acquiring an additional 8,123 shares in the last quarter. E Fund Management Co. Ltd. increased its position in Geron by 12.0% during the 2nd quarter. E Fund Management Co. Ltd. now owns 92,238 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 9,849 shares during the period. Finally, Velan Capital Investment Management LP lifted its position in shares of Geron by 14.3% in the 3rd quarter. Velan Capital Investment Management LP now owns 80,000 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 10,000 shares during the period. 73.71% of the stock is owned by institutional investors.

Geron Trading Down 5.7%

GERN opened at $1.48 on Friday. The company has a quick ratio of 4.96, a current ratio of 6.91 and a debt-to-equity ratio of 0.55. Geron Corporation has a 52 week low of $1.04 and a 52 week high of $2.01. The stock has a market cap of $950.86 million, a PE ratio of -13.45 and a beta of 0.61. The business has a 50 day moving average of $1.34 and a 200-day moving average of $1.46.

Geron (NASDAQ:GERN) last posted its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). The firm had revenue of $57.48 million during the quarter, compared to the consensus estimate of $55.30 million. Geron had a negative return on equity of 24.48% and a negative net margin of 34.17%. Equities research analysts predict that Geron Corporation will post -0.04 earnings per share for the current fiscal year.

Key Stories Impacting Geron

Here are the key news stories impacting Geron this week:

• Positive Sentiment: Geron reported record second-quarter revenue of $57.48 million, exceeding the $55.30 million analyst consensus, with growth attributed to demand for Rytelo. The revenue beat supports the commercial potential of the company’s lead product. Geron adds a record 16% as Rytelo drives Q2 revenue beat
• Positive Sentiment: Traders purchased a large volume of Geron call options, signaling that some market participants are positioning for potential upside in GERN. However, options activity does not guarantee a sustained move in the stock. Stock Traders Buy Large Volume of Geron Call Options
• Neutral Sentiment: Analyst opinions on Geron remain mixed, indicating uncertainty about the company’s earnings trajectory and the pace at which Rytelo can translate into profitability. Analysts’ Opinions Are Mixed on These Healthcare Stocks
• Negative Sentiment: Geron reported a second-quarter loss of $0.02 per share, missing the $0.01-per-share loss analysts expected. Its negative net margin and continued losses highlight that the company has not yet achieved profitability. Geron: Q2 Earnings Snapshot
• Negative Sentiment: HC Wainwright lowered its EPS forecasts across 2026 through 2030, including estimates of a $0.05 loss for 2026, $0.02 EPS for 2027, $0.12 for 2028, $0.32 for 2029 and $0.55 for 2030. The revisions suggest weaker near- and long-term earnings expectations, likely contributing to selling pressure. HC Wainwright Geron EPS Estimates

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of Geron from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 24th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $4.00.

Geron Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.